Table 1. Clinical Features of Patients... | American Society of Hematology

Table 1.

Clinical Features of Patients With AML With t(8; 21) With and Without CD56 Expression

Patient No.	CD56	Age/Sex	WBC	Induction Outcome	Intensification Therapy	CRD (mo)	Survival (mo)

1	+	27/M	14.2	CR	HDAC, VP/Cy, AZQ/Mito	9.0	22.0
2	+	54/F	6.4	CR	HDAC, VP/Cy, AZQ/Mito	6.5	9.0
3^*	+	67/M	7.6	CR	AraC/Mito × 3	7.9	10.2
4	+	52/M	39.7	CR	HDAC, VP/Cy	10.7	19.4
5	+	21/F	5.3	CR	HDAC, VP/Cy	6.9	19.1
6	+	39/M	34.6	CR	HDAC × 2	2.8	3.5
7	+	36/M	18.5	CR	HDAC, VP/Cy, AZQ/Mito	20.0	45.5+^†
8^*	+	48/F	30.7	CR	HDAC, VP/Cy, AZQ/Mito	7.7	11.4
9^*	+	51/F	85.7	CR	HDAV, VP/Cy, AZQ/Mito	8.5	10.9
10	+	27/M	2.6	CR	HDAC, VP/Cy	16.2	26.8+
11	+	37/F	45.3	CR	HDAC × 3	30.4+	31.3+
12^‡	+	28/F	57.6	RD			4.0
13^‡	+	51/M	7.7	D			1.1
14	+	49/M	43.6	CR	HDAC, VP/Cy, AZQ/Mito	21.6+	23.5+
15	+	33/M	30.3	CR	HDAC × 3	8.2	16.5
16	+	20/M	8.9	CR	HDAC × 3	13.4+	15.0+
17	−	23/M	6.4	CR	HDAC, VP/Cy, AZQ/Mito	57.0+	58.2+
18	−	45/M	4.0	CR	HDAC, AutoBMT	52.4+	53.0+
19	−	38/F	1.5	CR	HDAC, VP/Cy, AZQ/Mito	50.8+	52.2+
20	−	22/M	10.5	RD			48.2+^†
21	−	67/F	9.1	CR	Ara-C × 2	7.5	11.7
22	−	53/M	11.1	CR	HDAC × 3	28.2+	29.5+
23	−	29/M	12.7	CR	HDAC × 2	22.6+	24.4+
24	−	32/M	8.6	CR	HDAC × 1	28.2+	28.6+
25	−	31/M	1.6	CR	HDAC × 2	2.4	3.8
26	−	37/F	37.7	CR	HDAC, VP/Cy, AZQ/Mito	21.5+	23.1+
27	−	48/M	14.0	CR	HDAC, VP/Cy, AZQ/Mito	16.2+	18.5+
28	−	29/M	18.6	CR	HDAC × 1	11.0	12.9+
29	−	51/F	30.1	CR	HDAC, VP/Cy, AZQ/Mito	10.3+	12.0+

Patient No.	CD56	Age/Sex	WBC	Induction Outcome	Intensification Therapy	CRD (mo)	Survival (mo)

1	+	27/M	14.2	CR	HDAC, VP/Cy, AZQ/Mito	9.0	22.0
2	+	54/F	6.4	CR	HDAC, VP/Cy, AZQ/Mito	6.5	9.0
3^*	+	67/M	7.6	CR	AraC/Mito × 3	7.9	10.2
4	+	52/M	39.7	CR	HDAC, VP/Cy	10.7	19.4
5	+	21/F	5.3	CR	HDAC, VP/Cy	6.9	19.1
6	+	39/M	34.6	CR	HDAC × 2	2.8	3.5
7	+	36/M	18.5	CR	HDAC, VP/Cy, AZQ/Mito	20.0	45.5+^†
8^*	+	48/F	30.7	CR	HDAC, VP/Cy, AZQ/Mito	7.7	11.4
9^*	+	51/F	85.7	CR	HDAV, VP/Cy, AZQ/Mito	8.5	10.9
10	+	27/M	2.6	CR	HDAC, VP/Cy	16.2	26.8+
11	+	37/F	45.3	CR	HDAC × 3	30.4+	31.3+
12^‡	+	28/F	57.6	RD			4.0
13^‡	+	51/M	7.7	D			1.1
14	+	49/M	43.6	CR	HDAC, VP/Cy, AZQ/Mito	21.6+	23.5+
15	+	33/M	30.3	CR	HDAC × 3	8.2	16.5
16	+	20/M	8.9	CR	HDAC × 3	13.4+	15.0+
17	−	23/M	6.4	CR	HDAC, VP/Cy, AZQ/Mito	57.0+	58.2+
18	−	45/M	4.0	CR	HDAC, AutoBMT	52.4+	53.0+
19	−	38/F	1.5	CR	HDAC, VP/Cy, AZQ/Mito	50.8+	52.2+
20	−	22/M	10.5	RD			48.2+^†
21	−	67/F	9.1	CR	Ara-C × 2	7.5	11.7
22	−	53/M	11.1	CR	HDAC × 3	28.2+	29.5+
23	−	29/M	12.7	CR	HDAC × 2	22.6+	24.4+
24	−	32/M	8.6	CR	HDAC × 1	28.2+	28.6+
25	−	31/M	1.6	CR	HDAC × 2	2.4	3.8
26	−	37/F	37.7	CR	HDAC, VP/Cy, AZQ/Mito	21.5+	23.1+
27	−	48/M	14.0	CR	HDAC, VP/Cy, AZQ/Mito	16.2+	18.5+
28	−	29/M	18.6	CR	HDAC × 1	11.0	12.9+
29	−	51/F	30.1	CR	HDAC, VP/Cy, AZQ/Mito	10.3+	12.0+

Abbreviations: WBC, white blood cell count (×10⁹/L); CR, complete remission; RD, resistant disease; D, died; CRD, CR duration; HDAC, high-dose cytarabine; VP, etoposide; CY, cyclophosphamide; AZQ, diazoquinone; Mitox, mitoxantrone; AraC, cytarabine; BMT, bone marrow transplantation; auto, autologous.

Granulocytic sarcoma at relapse.

†

Bone marrow transplantation after relapse or resistant disease.

‡

Granulocyte sarcoma at diagnosis.

View Large

This Feature Is Available To Subscribers Only